ACADIA Pharmaceuticals Revenue by Product

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
NUPLAZID	668.61M	650.27M	639.20M	609.42M	590.42M	576.06M	560.67M	549.21M
NUPLAZID Growth	13.24%	12.88%	14.01%	10.96%	8.97%	9.17%	7.77%	6.17%
DAYBUE	378.49M	368.60M	357.07M	348.38M	338.78M	314.43M	253.10M	-	-	-	-	-	-	-	-	-	-	-	-	-
DAYBUE Growth	11.72%	17.23%	41.08%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.